Avastin plus R-CHOP trial for DLBCL halted for safety reasons
An independent safety monitoring board has recommended that Roche, makers of Avastin, stop enrolling patients in a phase III trial that had been designed to test the safety and efficacy of adding Avastin to R-CHOP for the treatment of patients with diffuse large B-cell lymphoma (DLBCL).
The recommendation was made after initial data from 720 patients indicated that the benefits did not outweigh the risks.
Avastin remains Roche's biggest selling cancer drug despite this, and despite the fact that the drug failed to provide any benefits in previous trials to patients with gastric and prostate cancers.
Nonetheless, the drug is FDA approved in various combinations for metastatic colorectal cancer, non-small cell lung cancer, metastatic breast cancer, metastatic kidney cancer, and glioblastoma.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
